"Patients on chemotherapy should not ignore symptoms like fatigue, thinking it's just related to the chemotherapy. The treating physician should be made aware of these symptoms, as this could lead to ...

Please provide your email address to receive an email when new articles are posted on . A liberal vs. restrictive transfusion strategy yielded similar rates of death or MI at 30 days in patients with ...

Please provide your email address to receive an email when new articles are posted on . In patients with anemia who present with MI, a restrictive blood transfusion strategy was noninferior to liberal ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...

A National Institutes of Health-supported study found that the type of transfusion approach used to support adults who developed anemia after a heart attack did not make a significant difference in ...

The phase 3 MATTERHORN trial examining roxadustat as an anemia treatment in patients with transfusion-dependent, lower-risk myelodysplastic syndrome did not meet its primary end point. The phase 3 ...

Patients living with myelofibrosis who also experience anemia may see meaningful improvements in blood counts when treated ...

Anemia occurs frequently in patients with cancer, with estimates reaching as high as 90% in those with solid tumors. The red blood cell disorder, which may develop because of tumor-related features or ...

To correct anemia in renal transplant candidates, we transfuse blood. Is it necessary to wait for 2 to 4 weeks posttransfusion before renal transplantation, even if the lymphocyte cross-match is ...

Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, has been awarded a three-year Small Business Innovation Research Grant (SBIR) Phase II for a project titled ...

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the Committee ...